Burning Rock Biotech Limited (NASDAQ:BNR) Short Interest Update

Burning Rock Biotech Limited (NASDAQ:BNR) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 60,500 shares, a decline of 6.6% from the December 31st total of 64,800 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 2.3 days.

Burning Rock Biotech Price Performance

BNR traded down $0.05 during midday trading on Monday, reaching $6.64. 6,883 shares of the company’s stock traded hands, compared to its average volume of 5,278. The firm has a fifty day moving average of $6.66 and a two-hundred day moving average of $5.32. Burning Rock Biotech has a 52 week low of $2.62 and a 52 week high of $8.99. The stock has a market capitalization of $67.97 million, a price-to-earnings ratio of -2.21 and a beta of 0.55.

Burning Rock Biotech (NASDAQ:BNR) last issued its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.50) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.